Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-Current Debt (2020 - 2025)

Rani Therapeutics Holdings' Non-Current Debt history spans 5 years, with the latest figure at $2.2 million for Q2 2025.

  • On a quarterly basis, Non-Current Debt fell 87.05% to $2.2 million in Q2 2025 year-over-year; TTM through Jun 2025 was $2.2 million, a 87.05% decrease, with the full-year FY2024 number at $9.6 million, down 60.74% from a year prior.
  • Non-Current Debt came in at $2.2 million for Q2 2025, down from $5.9 million in the prior quarter.
  • The five-year high for Non-Current Debt was $29.3 million in Q2 2023, with the low at $2.2 million in Q2 2025.
  • Historically, Non-Current Debt has averaged $18.6 million across 4 years, with a median of $19.0 million in 2024.
  • Biggest five-year swings in Non-Current Debt: soared 99.43% in 2023 and later plummeted 87.05% in 2025.
  • Year by year, Non-Current Debt stood at $29.1 million in 2022, then fell by 16.0% to $24.5 million in 2023, then tumbled by 60.74% to $9.6 million in 2024, then tumbled by 76.81% to $2.2 million in 2025.
  • Business Quant data shows Non-Current Debt for RANI at $2.2 million in Q2 2025, $5.9 million in Q1 2025, and $9.6 million in Q4 2024.